Published On: May 1st, 2020Categories: Intellectual Property, IP Management, Patent Applications, Patents

COVID-19 has infected over 3,257,996 people and claimed more than 233,429 lives globally (Source: JHU). This article addresses ongoing efforts to develop therapeutics, particularly novel vaccine candidates.

The present article is an update to our earlier coverage on COVID19

Figure 1 – Clinical Trial; Data Source: ClinicalTrials.gov

The number of clinical trials related to COVID-19 registered at various international and national clinical trial registries has increased dramatically to over 900 since our last update. Approximately 75% of these trials were initiated in the last month alone. Data from the National Institute of Health indicates that the majority of clinical trials are at advanced stages and are being conducted in countries reporting larger COVID-19 cases such as the United States, France, China, Spain, Italy, and the United Kingdom.

image5-72image4-78

Figure 2 – Clinical Trial By Phase(left) and Intervention (right); Data Source: ClinicalTrials.gov

The advanced nature of the ongoing trials is due to drug repurposing efforts. These efforts are focussing on the safety and efficacy of medicines that have already been developed for similar Corona viruses and other diseases. Some of these include remdesivir, chloroquine/hydroxychloroquine, favipiravir, lopinavir–ritonavir, plasma therapy, stem-cell transfusion, vaccines and traditional Chinese medicines. Hydroxychloroquine, touted as a game-changer, is the most studied drug in the US with over 33 different trials. Although a combination of hydroxychloroquine with Azithromycin (a subject of 11 trials) has been suggested as a therapeutic option for the disease, some experts have raised concerns about the combination in some patient groups. Therapeutic antibodies such as tocilizumab, sarilumab, eculizumab, and nivolumab are also being tested in various clinical trials as immunomodulators.

Figure 3: SARS-CoV-2 (COVID-19) is a single-stranded RNA virus made of 29,903 base pairs that is predicted to code for 24 viral proteins. Genes for the conserved and major structural proteins occur 5’-3’ in the order: Spike (S), envelope (E), membrane (M) and nucleocapsid (N). SARS-CoV-2 binds to the cellular ligand ACE2 (the angiotensin-converting enzyme 2) in the host by its Spike (S) which allows the virus to enter and infect cells. The spike protein (S) has to be primed by a protease called TMPRSS2 for entry into the host cell.

The availability of the genomic and structural information from early samples has accelerated vaccine development efforts. There are more than 90 vaccine candidates in the development pipeline across the world. At least six of these are being tested in human clinical trials. The vaccine candidates come in many forms, including viral vaccines (inactivated or attenuated), subunit vaccines (peptide or virus-like particles), viral vectors (replicating or non-replicating), and nucleic-acid based vaccines (DNA or RNA).

Table 1, below, lists selected vaccines that are being tested at various stages of human clinical trials. The target antigen for many of these candidates is unknown although spike protein-based antigens appear to be an attractive option based on earlier studies of previous coronaviruses. The spike protein is a previously studied target on other coronaviruses. It mediates the binding of the virus to the host cell receptors and enables viral entry into the cell. The generated neutralizing antibodies from vaccine candidates is expected to prevent uptake of the virus via ACE2.

Company/ Institute Vaccine Name Type of Vaccine

Clinical Trial Details

Moderna/NIAID mRNA-1273 mRNA
(nucleic-acid based)
NCT04283461
Inovio INO-4800 DNA
(nucleic-acid based)
NCT04336410
CanSino Biological Ad5-nCoV Adenovirus
(Non-replicating viral vector)
NCT04313127;

ChiCTR2000031781

Oxford Biomedica/University of Oxford COV001 (ChAdOx1 nCoV-19) Adenovirus
(Non-replicating viral vector)
NCT04324606
Sinovac NA Inactivated
(Viral)
NCT04352608
Sinopharm/ Wuhan Institute of Virology COVID-19 vaccine (Vero cells) Inactivated
(Viral)

ChiCTR2000031809

Table 1 – Selected Vaccines that have entered Clinical Testing Stage as of April 26, 2020; Source: WHO

Some developers are focusing on next-generation platforms such as nucleic-acid based vaccines. Moderna Therapeutics, a unicorn company backed by a large patent portfolio, is betting big on its RNA-based therapeutic platform. Its synthetic vaccine candidate mRNA-1273, jointly developed with NIAID-NIH, is based on the spike protein (S). The mRNA vaccine, if successful, could be synthesised quickly, enabling quick scale-up and manufacturing.

Developing vaccines in a short-frame will require varied expertise and pooling of resources. For example, Inovio has recently partnered with Richter-Helm Biologics to scale up the manufacturing of its vaccine candidate, INO-4800, an investigational DNA vaccine backed by a patent portfolio built around Inovio’s DNA medicine platform.

Table 2 lists additional partnerships between pharmaceutical companies, contract manufacturers, universities and research institutes aimed at developing effective and safe treatments for COVID19.

 

Date Companies Focus area Details
27-Apr-20 Merck/ Institute for Systems Biology Biomarkers To identify targets for medicine and vaccine
06-Apr-20 Glaxosmithkline/ Vir Biotechnology Antibodies To develop mAbs against SARS-CoV-2
03-Apr-20 XBiotech and BioBridge Global Convalescent Plasma To begin collecting and distributing convalescent plasma
02-Apr-20 Amgen / Adaptive Biotechnologies Antibodies To develop fully human neutralizing antibodies
01-Apr-20 Neurimmune/ Ethris mRNA-based Antibody Treatment To develop an immunotherapy 
27-Mar-20 Sanofi Pasteur/ Translate Bio Vaccine To develop an mRNA vaccine
25-Mar-20 Xencor / Vir Biotechnology Antibodies To develop mAbs for treating COVID19
24-Mar-20 Dynavax/Clover Vaccine To provide adjuvant for the vaccine candidate COVID-19 S-Trimer
24-Mar-20 Akers Biosciences/ Premas Biotech Vaccine To develop a vaccine using S. cerevisiae platform, D-Crypt™
17-Mar-20 Pfizer/ Biontech Vaccine To develop the mRNA vaccine BNT162
16-Mar-20 Biontech/Fosun Vaccine To develop BNT162 in China
13-Mar-20 J&J/ Beth Israel Vaccine To develop a preventive vaccine
12-Mar-20 Vir Biotechnology /Biogen Antibodies To manufacture mAbs
12-Mar-20 Eli Lilly/Abcellera Antibodies To develop mAbs against SARS-CoV-2
10-Mar-20 Emergent Biosolutions/Noavax Vaccine To use adjuvant Matrix-M™ for vaccine development
24-Feb-20 Clover/ GSK Vaccine To develop protein based vaccine COVID-19 S-Trimer
12-Feb-20 Vir Biotechnology /WuXi Antibodies To advance and produce human monoclonal antibodies

Table 2: Selected Partnerships and Collaborations Between Pharma Companies towards the Fight against COVID19

Traditional vaccine development is a long and drawn out process that can typically take five to ten years. However, we are in unprecedented times. The scale and speed of the global response to the COVID-19 pandemic is evident by the sheer number of vaccine candidates, developers and clinical trials that are already progressing. This outbreak has motivated many companies to shift their priorities, refocus and race towards developing the cure for COVID-19. Some experts believe effective COVID19 vaccines may become available as early as 2021.

 

Have any content requests?

You can let us know at [email protected]

Get the latest IP data, insights and inspiration directly delivered to your inbox

Categories